$BXP

BXP Inc. announced it will maintain its quarterly dividend at $0.70 per share, payable on October 30 to shareholders of record on September 30. The company's stock has seen a 5-day change of +0.31%, a 1st Jan change of -0.39%, and a year-to-date change of -5.10%.

Beximco Pharmaceuticals PLC clarifies press reports suggesting Salman F Rahman may resign as Vice-Chairman. The company is in discussions with BSEC about potential board changes, subject to final agreement and due diligence. The matter is tied to ongoing legal cases in Bangladesh's High Court.

U.S. real estate stocks declined as investors increased expectations for a September Fed rate hike to 55%, up from 35.4%. The S&P 500 Real Estate sector fell 1.28%, while XLRE dropped 1.33% to $44.48. Host Hotels & Resorts (HST) and Iron Mountain (IRM) led large-cap decliners, while SBA Communications (SBAC) gained 4.58%. Fermi (FRMI) and Real REMAX Group (REAX) were among the notable mid and small-cap losers.

Vieron Capital acquired a 210K SF office complex in D.C. from BXP for $66.8M, financed partly by a $31M loan from Bank of America. BXP recorded a $35M impairment charge on the sale. BXP is also selling another D.C. property and developing new office projects. Other D.C. real estate deals included leases and sales involving Jemal Equities, In-Rel Properties, and Douglas Development Corp.

BXP reported Q2 2026 earnings exceeding expectations and raised its full-year FFO outlook, citing improved business fundamentals. The company's investment narrative hinges on high-quality office and life science space in key markets, with risks tied to new developments and leasing. BXP's $1.2B construction loan for 343 Madison Avenue highlights both potential and risks. Analysts' earnings estimates for 2029 range from $290.1M to $343.6M, with revenue projections between $3.7B and $3.8B.

Analysts covering BXP stock have a consensus 'Moderate Buy' rating, with 11 'Strong Buy' and 12 'Hold' ratings. This is more bullish than three months ago. Deutsche Bank maintained a 'Hold' rating with a $70 price target. The mean target is $74.26, a 9.7% premium to current levels, with a high target of $90.

JPMorgan raised its price target for BXP to $87 from $79. The stock has a 5-day change of $69.99, with a 3.43% increase and a 4.95% year-to-date gain. BMO Capital also adjusted its target to $75 from $68.

BXP, Inc. reports improved leasing and rising occupancy, with 106 leases covering 1.8M sq ft in Q2. Portfolio occupancy reached 88.4%, and management targets 91% by 2027. BXP trades at 9.3X forward earnings, below industry and sector averages. However, uneven rent spreads, development risks, and potential refinancing costs pose challenges. BXP shares rose 13.4% over three months, underperforming SL Green but outperforming Kilroy.

BXP closed a $1.2B loan for its $2B 343 Madison Ave project, reducing equity needs to $341M. The 4-year loan at Term SOFR + 2.50% (declining to +2.25% upon milestones) funds 60% of costs. BXP targets 7.5%-8% returns, pending leasing and construction progress. The project is 50% pre-leased, with delivery expected in late 2029.

Hoya Capital reports that 83% of U.S. REITs raised full-year FFO guidance in Q2 2026, with strong performance in hospitality, industrial, and office sectors. SL Green and BXP led office sector gains. Despite strong earnings, high interest rates dampened investor sentiment, with the Equity REIT Index down 0.7% in July-August. Hospitality REITs saw 10.6% FFO growth, while industrial REITs reported 4.4% FFO growth. Residential REITs faced challenges due to high supply and interest rates.